| Symbol | VRPX |
|---|---|
| Name | VIRPAX PHARMACEUTICALS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 19312 United States PA 1055 Westlakes Drive Suite 300 |
| Telephone | (610) 727-4597 |
| Fax | — |
| — | |
| Website | https://virpaxpharma.com/ |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | EisnerAmper LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001708331 |
| Description | Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The companys preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Additional info from OTC: |
New Form 25-NSE - Virpax Pharmaceuticals, Inc. Filed: 2025-07-21 AccNo: 0001354457-25-000708 Size: 4 KB
Read moreVirpax Pharmaceuticals Inc (VRPX) was removed from the list of traded instruments on NASDAQ exchange
Read moreNASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNASDAQ symbol attribute type Security_Name was changed. Previous value: Virpax Pharmaceuticals, Inc. - Common Stock. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNASDAQ traded attribute type Security_Name was changed. Previous value: Virpax Pharmaceuticals, Inc. - Common Stock. New value: Virpax Pharmaceuticals, Inc. - Common Stock.
Read moreNew Form 8-K/A - Virpax Pharmaceuticals, Inc. Filed: 2025-04-03 AccNo: 0001731122-25-000524 Size: 206 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 5.02: Departure of Directors or Certain Officers; Election of Directors; App…
Read more